The growth of the global biologics safety testing market is
driven by factors such as the growth in the biologics and biosimilars markets,
growing concerns over cell culture contamination, and rising biopharmaceuticals
R&D activities and investments.
The global biologics
safety testing market is projected to reach USD 6.2 billion by 2026 from
USD 3.4 billion in 2021, at a CAGR of 12.4% during the forecast period.
Download PDF
Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34624144
Market
Segmentation
Based on test type, the biologics safety testing market is
segmented into residual host-cell proteins and DNA detection tests, endotoxin
tests, sterility tests, mycoplasma tests, bioburden tests, and virus safety
tests. In 2020, the residual host-cell proteins and DNA detection tests segment
accounted for the largest market share. The rising demand for residual HCP and
DNA detection tests for recombinant proteins and increasing focus on the
quality of drugs are the major factors driving the growth of this segment.
Based on application, the biologics safety testing market is
segmented into monoclonal antibodies manufacturing, vaccines manufacturing,
blood and blood products manufacturing, cellular and gene therapy products
manufacturing, and other applications. In 2020, the monoclonal antibodies
manufacturing segment accounted for the largest market share. The large share
of this segment can be attributed to the rising prevalence of diseases and
increasing government initiatives for the development of monoclonal antibody
drugs.
Regional Analysis:
The Asia Pacific market is projected to witness the highest
growth rate during the forecast period, primarily due to the expansion of key
market players in emerging Asia Pacific countries, increasing expenditure on
life science research, and the increasing trend of pharmaceutical outsourcing
to Asia Pacific countries.
Key Market Players:
Prominent players in the biologics safety testing market are Charles River Laboratories, Inc. (US), Lonza (Switzerland), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), SGS SA (Switzerland), WuXi AppTec (China), and Eurofins Scientific (Luxembourg).
CHARLES RIVER LABRATORIES (US)
Charles River is one of the key players in the biologics
safety testing market, it is a service and early-stage contract research
organization (CRO). The company develops a diverse portfolio of discovery and
safety assessment services and provides a suite of products and services to
support its clients’ manufacturing activities.